Physician profile
Sheena Moorthy
NPI 1649768722
$2,134.80
in general payments reported to CMS, 2019-2025
18 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.91 · 2022: $422 · 2023: $879 · 2024: $481 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $799.53 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $340.00 | 2022-2025 | Eliquis, Camzyos |
| Abbvie INC. | $189.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $121.73 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $110.96 | 2021-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $97.93 | 2023-2024 | Dificid, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.09 | 2024-2025 | Xifaxan |
| Pfizer INC. | $78.88 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $59.68 | 2024-2025 | Terlivaz |
| Paratek Pharmaceuticals, INC. | $49.20 | 2023 | Nuzyra |
| Evoke Pharma, INC. | $31.52 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $30.93 | 2024 | |
| Janssen Biotech, INC. | $27.03 | 2025 | Tecvayli, Talvey |
| Actelion Pharmaceuticals US, INC. | $26.98 | 2022 | |
| Novo Nordisk INC | $22.09 | 2024 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2022 | |
| Recordati_rare_diseases_inc. | $18.62 | 2024 | Panhematin |
| Gilead Sciences, INC. | $14.32 | 2025 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Moorthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.